Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic Study of AZD3427 in Heart Failure
NCT04890548Phase 1Withdrawn
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, open-label trial of AZD3427 in heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) (2 cohorts), sponsored by AstraZeneca. Primary endpoint: Maximum change from baseline in absolute forearm blood flow at Day 1. Planned start Nov 2021; status: withdrawn.
02
Drugs
AZD3427
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04890548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890548.